Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status-Reference-Cited by-同舟云学术

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status

Published:2019-11-08 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Loupakis Fotios^ORCID,Maddalena Giulia,Depetris Ilaria,Murgioni Sabina,Bergamo Francesca,Dei Tos Angelo Paolo,Rugge Massimo,Munari Giada,Nguyen Andrew,Szeto Christopher,Zagonel Vittorina,Lonardi Sara,Fassan Matteo

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0788-5.pdf

Reference29 articles.

1. Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35:1453–86.

2. Rubenstein JH, Enns R, Heidelbaugh J, et al. American gastroenterological association institute guideline on the diagnosis and management of lynch syndrome. Gastroenterology. 2015;149:777–82; quiz e16–7.

3. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.

4. Jover R, Zapater P, Castells A, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer. 2009;45:365–73.

5. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182–91.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors;British Journal of Cancer;2024-09-13

2. Resistance to immune checkpoint inhibitors in colorectal cancer with deficient mismatch repair/microsatellite instability: misdiagnosis, pseudoprogression and/or tumor heterogeneity?;Exploration of Targeted Anti-tumor Therapy;2024-05-23

3. Liquid biopsy in colorectal cancer: Onward and upward;Critical Reviews in Oncology/Hematology;2024-02

4. Prevalence and type of MMR expression heterogeneity in colorectal adenocarcinoma: therapeutic implications and reporting;Virchows Archiv;2023-12-23

5. Cholesterol in colorectal cancer: an essential but tumorigenic precursor?;Frontiers in Oncology;2023-11-03